Supplemental material
Journal of Medical Economics
Volume 25, 2022 - Issue 1
Infectious Diseases
Hospitalization costs of adult community-acquired pneumonia in England
James Camplinga Vaccines Medical Affairs, Pfizer Ltd. UK, Tadworth, Surrey, UKCorrespondence[email protected]
https://orcid.org/0000-0002-6886-8565
https://orcid.org/0000-0002-6886-8565, Hannah F. Wrighta Vaccines Medical Affairs, Pfizer Ltd. UK, Tadworth, Surrey, UKhttps://orcid.org/0000-0001-8328-7294
https://orcid.org/0000-0001-8328-7294, Gillian C. Hallb Gillian Hall Epidemiology Ltd., London, UKhttps://orcid.org/0000-0001-5081-3710
https://orcid.org/0000-0001-5081-3710, Tendai Mugwagwac Health & Value, Pfizer Ltd. UK, Tadworth, Surrey, UKhttps://orcid.org/0000-0001-7515-8548
https://orcid.org/0000-0001-7515-8548, Andrew Vysea Vaccines Medical Affairs, Pfizer Ltd. UK, Tadworth, Surrey, UKhttps://orcid.org/0000-0002-0339-7491
https://orcid.org/0000-0002-0339-7491, Diana Mendesc Health & Value, Pfizer Ltd. UK, Tadworth, Surrey, UKhttps://orcid.org/0000-0002-1672-4906
https://orcid.org/0000-0002-1672-4906, Mary P. E. Slackd School of Medicine & Dentistry, Griffith University, Southport, Queensland, Australiahttps://orcid.org/0000-0001-5119-4085
https://orcid.org/0000-0001-5119-4085 & Gillian F. Ellsburya Vaccines Medical Affairs, Pfizer Ltd. UK, Tadworth, Surrey, UKhttps://orcid.org/0000-0002-6855-4080
https://orcid.org/0000-0002-6855-4080 show all